August 2026 in Oncology: A Look Back at FDA Approvals and Decisions

August 2026 saw the FDA take action across a diverse range of oncology indications, with several decisions introducing novel treatment options while a series of regulatory designations advanced promising therapies through the development pipeline. The month brought notable milestones in multiple myeloma, gastroesophageal adenocarcinoma, and metastatic pancreatic cancer, alongside growing momentum for biomarker-driven strategies in breast cancer, lung cancer, glioma, and other solid tumors.